Frontlight ResearchEarly access
WithdrawnNo phase
A Study in Patients With Complicated Type B Aortic Dissection Treated With the E-nya Thoracic Stent Graft
Key facts
- Who runs it
- JOTEC GmbH
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 25 May 2020
- Ended
- 24 Jul 2024
- Type of study
- Observational
- Treatments tested
- endovascular repair
- Record updated
- 25 July 2024
- Why it stopped
- Expiry of CE mark.
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Age between 18 and 85 years
- Complicated acute, subacute or chronic type B aortic dissection with evidence of at least one of the following:; Malperfusion (visceral, renal, spinal cord and/or lower limb ischemia); Three of the following risk factors in acute or subacute dissections; Young patient; Primary entry tear > 10 mm; Early aortic expansion > 5 mm within 6 months; Total aortic diameter > 40 mm; False lumen diameter > 20 mm; Partially thrombosed false lumen; Total diameter > 50 mm in case of chronic dissections
- Patient is hemodynamically stable (stable blood pressure and heart rate, no shock)
- Planned proximal and distal landing zone of the E-nya Thoracic Stent Graft component(s) in the native aorta
- Landing zone of the proximal edge of the fabric distal to the left carotid artery
- Landing zone of the distal edge of the fabric proximal to the celiac trunk
- Proximal landing zone diameter between 20 and 44 mm
- Centerline distance from the distal edge of the left carotid artery to the start of the most proximal tear ≥ 20 mm
- Thoracic aortic lesion confirmed by thin sliced (≤ 1 mm) CTA with optional three-dimensional reconstruction obtained within 3 months prior to the implant procedure
- Patient is able and willing to undergo follow-up imaging and examinations prior to discharge from the hospital, at 30 days and 12 months, and annually thereafter until 5 years follow-up
- Patient understands and has signed the Informed Consent Form prior to intervention whenever possible or after the intervention in case the patient's status does not allow consent to be obtained prior to intervention
Who cannot take part
- Patients who are planned to be treated with a chimney in the left subclavian artery
- Patients who are planned to be treated with the Petticoat concept
- Previous stent and/or stent graft or previous surgical repair of descending thoracic aorta
- Patient had or planned to have a major surgical or interventional procedure within 30 days before or 30 days after the planned implantation of the E-nya Stent Graft System(s). This exclusion does not include planned procedures that are needed for the safe and effective placement of the stent graft (ie, carotid/subclavian transposition, carotid/subclavian bypass procedure)
- Genetic connective tissue diseases (e.g. Marfan Syndrome or Ehlers-Danlos Syndrome)
- Allergies against materials necessary for endovascular repair (e.g. contrast media, heparin, materials of the stent graft)
- Systemic or local infections
- Myocardial infarction or cerebrovascular accident < 3 months
- Patient has specified disease of the thoracic aorta which is not included in the registry, for example: intramural hematoma, penetrating aortic ulcer, traumatic injury or transection, (contained) aortic rupture (hemorrhage outside of aorta)
- Other medical condition that may cause the patient to be non-compliant with the protocol, confound the results, or is associated with a limited life expectancy (i.e. heart failure, active malignancy (progressive, stable or partial remission))
- eGFR < 45 ml/min/1.73m2 before the intervention
- Female of child bearing potential, breast feeding
- Access vessels not suitable for endovascular treatment
- Significant circular thrombi or calcification in proximal or distal landing zones
- Simultaneously participating in another clinical trial
- NYHA class IV
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The CONFORM-TAD post-market clinical follow-up study is undertakento evaluate the prevention of death related to the treatment of a complicated acute, subacute or chronic type B aortic dissection with the E-nya Thoracic Stent Graft System. The secondary objective is to evaluate safety and clinical performance of the device.
Treatments tested
- endovascular repair
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- CONFORM-TAD- A Post-market Clinical Follow-up Study in Patients With Complicated Acute, Subacute or Chronic Type B Aortic Dissection With Double Lumen Treated With the E-nya Thoracic Stent Graft System
- Record updated
- 25 July 2024